Darunavir: a new HIV-1 protease inhibitor for the treatment of HIV infection

摘要

Darunavir (formerly known as TMC 114) is a protease inhibitor that was approved by the US FDA in June 2006 for use in treatment-experienced patients, with markedly greater virological and immunological benefits compared with the standard of care. It is dosed twice daily with food and requires boosting with ritonavir. It has demonstrated virological efficacy in vivo, with activity against protease inhibitor-resistant HIV, and in treatment-naive patients in clinical studies with up to 48-week follow-up in combination with an optimized background regimen. Darunavir used with low-dose ritonavir is a largely well-tolerated protease inhibitor with proven efficacy.